Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2449results about "Amine active ingredients" patented technology

1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment

Provided are compounds of Formula I:nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2-haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.
Owner:GILEAD SCI INC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

SOS1 protein degraders, pharmaceutical compositions, and therapeutic applications

Provided herein are SOS1 protein degraders, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of an SOS1-mediated disorder, disease, or condition.
Owner:BIOTHERYX INC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

Compounds and combinations thereof for treating neurological and psychiatric conditions

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.
Owner:ANTECIP BIOVENTURES II LLC

NMDAR antagonists to prevent aging and aging-related conditions and diseases by increasing 20S proteasome activity

The use of NMDAR antagonists provides compositions and methods for the treatment of dysfunction of protein homeostasis networks that interfere with the key signaling pathways and are often associated with a variety of human diseases. Importantly, the present invention provides information comprising at least one NMDA receptor blocker for use in the prevention and / or treatment of aging and aging-related conditions and diseases by increasing 20S proteasome activity.
Owner:菲克雷特·萨欣

Stable pharmaceutical compositions

The present invention relates to a stable pharmaceutical composition of therapeutically active agent, wherein the amount of nitrosamine impurity is below the FDA acceptable intake limit for shelf life of the pharmaceutical composition and a process for preparing the same.
Owner:MANKIND PHARMA LTD

New application of small molecule compound BRD4780 in resisting ricin

The invention discloses a novel application of a small molecule compound BRD4780 in resisting ricin, the small molecule compound BRD4780 has a remarkable effect of resisting ricin toxicity and can be used in development of anti-ricin drugs, a brand new candidate molecule is provided for development of the anti-ricin drugs, the drug research and development blank in the field is filled, and the application of the small molecule compound BRD4780 in resisting ricin is developed. The method has important significance in the aspects of clinical treatment, biological protection and immunotoxin treatment safety optimization, and is wide in application prospect.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Hydrogen-bonded frameworks nanoparticles for SONO-optogenetic treatment of brain diseases

PCT designated stage expiredWO2025122626A1Nervous disorderOrganic chemistryOptogeneticsNanoparticle
Hydrogen-bonded framework nanoparticles comprising a chemiluminescent compound (e.g., L-012) are provided and can be used, e.g., for sono-optogenetic treatment of neurodegenerative diseases such as Parkinson's disease. Related in vivo and therapeutic methods are also provided.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

Correlation of AKR1c3 enzyme expression level with KRAS mutation, and medical use

Correlation of the AKR1C3 enzyme expression level with KRAS mutation, and a medical use. For an AKR1C3 enzyme activated anti-cancer prodrug, KRAS gene mutation can directly serve as a test target before drug administration, that is, a patient with KRAS mutation is the patient having a high AKR1C3 enzyme expression level and AKR1C3 enzyme expression level or AKR1C3 RNA testing is not required. That is to say, a positive KRAS mutation testing result can be used as a screening index to screen the patient having a high AKR1C3 enzyme expression level.
Owner:SHENZHEN ASCENTAWITS PHARM TECH CO LTD

Antagonists of the imidazoline-1 receptor for use in the prevention and / or treatment of an autoinflammatory or autoimmune disease

PCT designated stage expiredWO2025002914A1Amine active ingredientsCardiovascular disorderImidazoline receptorAutoimmune condition
The present invention refers to an antagonist of imidazoline-1 receptor (I1R) for use in the prevention and / or treatment of an autoinflammatory or autoimmune disease in a human subject, selected from the group consisting of (±)-2-endo-amino-3-exo- isopropylbicyclo[2.2.1]heptane (synonym: AGN192403), N-benzylguanidine, 2-(2- Fluoro-5-methylphenyl)-4,5-dihydro-1H-imidazole (synonym: S23757), 2-(2-chloro-4-iodo-phenylamino)-5-methyl-pyrroline (synonym: LNP911), 1-(4, 5-dihydro-1H-imidazol- 2-yl)isoquinoline (synonym: BU98008), 5-[2-bromophenoxy)methyl]-4,5-dihydro-1,3- oxazol-2-amine (synonym: S23515), 6-methylamino-2methylheptene (synonym: isometheptene), and 4-chloro-2,3-dihydro-2-oxo-1,3-benzothiazol-3-ylacetic acid (synonym: benazolin). Also, to the use of Imidazole propionate in the diagnosis of an autoinflammatory or autoimmune disease in a subject, and further to a method of diagnosis of atherosclerosis comprising assessing the level of ImP in a blood sample and determining whether said level is above or below a value of 41nM.
Owner:FUNDACION CENT NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CARLOS III (CNIC)

Use of benzethonium chloride in preparing medicine for improving or treating non-alcoholic fatty liver disease

The present invention relates to a use of benzethonium chloride in preparing a drug for improving or treating non-alcoholic fatty liver disease, and relates to the technical field of new uses of products. The present invention discovers for the first time a new use of benzethonium chloride for improving or treating non-alcoholic fatty liver disease. Benzethonium chloride can reduce hepatocyte lipid deposition and regulate hepatocyte lipid metabolism disorder by intervening in a cell lipid deposition model; it can improve liver lipid accumulation in mice caused by lipid metabolism disorder by administering through the digestive tract, and can improve liver coefficient, liver function, hepatic lobular inflammation, and liver fibrosis. The benzethonium chloride of the present invention can be used for the preparation of drugs for improving or treating non-alcoholic fatty liver disease. The benzethonium chloride of the present invention can inhibit the expression of human apolipoprotein C3, thereby reducing the generation of lipids, and is applied to drugs for treating non-alcoholic fatty liver disease, opening up a new use of benzethonium chloride and providing a new drug option for treating non-alcoholic fatty liver disease.
Owner:CHANGCHUN NORMAL UNIV

Methods of treating neuropsychiatric disorders with non-hallucinogenic tryptamines

PCT designated stage expiredWO2025122513A1Amine active ingredientsDrageesDiseasePsychogenic disease
Disclosed herein are compounds, compositions, and methods for promoting neuronal growth and / or improving neuronal structure with the compounds and compositions disclosed herein. Also described are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with non-hallucinogenic psychoplastogens.
Owner:DELIX THERAPEUTICS INC

Topical composition comprised of cod liver oil for treating wounds and skin disorders

Disclosed is a topical anhydrous, homogenous pharmaceutical composition for treating skin disorder and wounds comprising cod liver oil, hempseed oil, monolaurin, medium chain triglycerides (“MCT”), free fatty acids, sea salt, and vegetable oil selected from the group consisting of red palm concentrate, coconut oil, and red palm oil and combination thereof and optionally fish collagen, ascorbyl palmitate, thickening agent, such as beeswax, red palm concentrate and cetyl ester.
Owner:OMEZA HOLDINGS INC

Lipid emulsion for parenteral nutrition comprising GPC

The present disclosure relates to parenteral nutritional formulations, including ready-to-use parenteral nutrition formulations. More particularly, the present disclosure is directed to lipid formulations or emulsions and multi-chamber containers comprising same, wherein the lipid emulsion contains glycerophosphorylcholine as a choline source. The present disclosure further relates to methods of providing choline to a patient in need of parenteral nutrition and methods of avoiding and / or treating choline deficiency and liver damage.
Owner:BAXTER INT INC +1

Therapeutic methods and compositions for treating movement disorders

The invention provides therapeutic methods, pharmaceutical compositions, and unit dose formulations for treating movement disorders, such as using a muscarinic acetylcholine receptor inhibitor in combination with a muscarinic acetylcholine receptor activator to treat dystonia. In some aspects, the invention provides a method of treating a movement disorder in a patient, where the method comprises administering to a patient in need thereof (i) a muscarinic acetylcholine receptor inhibitor in an amount effective to treat the movement disorder and (ii) a muscarinic acetylcholine receptor activator in an amount effective to reduce the frequency and / or magnitude of at least one side effect of the muscarinic acetylcholine receptor inhibitor, to thereby treat the movement disorder.
Owner:VIMA THERAPEUTICS INC

Optimised dosage of diaminophenothiazines in populations

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.
Owner:WISTA LAB LTD

Optimised dosage of diaminophenothiazines in populations

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.
Owner:WISTA LAB LTD

Antiviral and bactericidal gel and preparation system thereof

The invention discloses an antiviral and bactericidal gel and a preparation system thereof, and relates to the technical field of gel preparation. Comprising a mixing device used for mixing materials, the mixing device comprises a lower tank body, and a middle tank body is integrally arranged at the top of the lower tank body; the upper tank body is arranged on the outer wall of the top of the middle tank body; the partition plate is fixed on the inner wall of the middle tank body, a plurality of groups of through holes are formed in the partition plate, and the interior of the upper tank body is communicated with the interior of the lower tank body through the through holes. By arranging the mixing device, the mixing device can work based on the stirring driving mechanism to drive the rotating main shaft to rotate, and then the upper stirring frame and the lower stirring frame are driven to stir and mix internal materials; the problems that part of materials such as suaeda glauca are prone to caking in the mixing process, and the suaeda glauca powder in the caking state floats on the liquid level more easily due to the fact that air is wrapped in the caking, so that local mixing is insufficient, and the mixing efficiency is low are solved.
Owner:PANJIN YUYUAN NEW CREATIVE DEV & PROMOTION CO LTD

Aldoximes as no donors, and their uses as plant architecture modifiers and in therapy

PCT designated stage expiredWO2025026555A1Organic chemistryAntipyreticDiseaseNutrition
It relates to aldoximes or pharmaceutically acceptable salts thereof or isomers thereof able of releasing nitric oxide (NO) for use in the treatment of a condition or a disease which is sensible to the action of the NO, wherein the treatment comprises administering the aldoxime to a subject and releasing NO from the aldoxime through an in vivo enzymatically catalyzed redox reaction at physiological pH, as well as to the in vivo use of such aldoximes or acceptable salts for plants thereof or isomers thereof for biological applications which are sensible to the action of the NO in plants, wherein the biological application is selected from the group consisting of plant rooting agent, plant structure modifier, stimulators of the tolerance to abiotic or biotic stress, plant protector from stress induced by ammonium nutrition as an exclusive source of nitrogen, plants protector from hydric stress, and as germination inducer. It also relates to compositions comprising them.
Owner:UNIV PUBLICA DE NAVARRA PAMPLONA +2

Oral instant film with high drug loading capacity

The invention belongs to the technical field of pharmaceutical preparations, and particularly relates to an oral instant film with high drug loading capacity. The oral instant film agent comprises the following components: an active component, a film-forming material, a plasticizer, a coloring agent and a flavoring agent. The film-forming material is preferably combined with hydroxypropyl methylcellulose E15 and xanthan gum, so that the high drug loading capacity of the oral cavity instant film agent is ensured. Film-forming materials including hydroxypropyl methylcellulose E15 and xanthan gum are combined and compounded with a plasticizer polyethylene glycol 400, and sucralose is adopted as a flavoring agent, so that the stability of the oral instant film agent is ensured. The oral cavity instant film is good in appearance property, moderate in flexibility, good in taste, high in drug loading capacity, good in stability, low in cost, easy to operate, free of heating and suitable for industrial production.
Owner:BEIJING XINLINGXIAN MEDICAL TECH DEV CO LTD

Rhodamine anti-cancer fluorescent compound with adjustably modified bridge oxygen sites as well as preparation method and application of rhodamine anti-cancer fluorescent compound

The invention relates to the technical field of medical chemistry, in particular to a bridge oxygen site regulatively modified rhodamine anti-cancer fluorescent compound as well as a preparation method and application thereof. The invention develops the rhodamine anti-cancer fluorescent compound of which the meso site is functionalized by tetraarylethene and the bridge oxygen site can be regulated and modified, the fluorescent compound has adjustable red light-near infrared fluorescence emission and excellent fluorescence quantum yield, and the quantum yield can be as high as 99%; the fluorescent compound specifically targets mitochondria, and mainly inhibits growth of tumor cells by inducing para-apoptosis; under irradiation of 655 nm near-infrared laser, ferroptosis is further triggered, efficient treatment of tumor cells is achieved through chemical-photodynamic synergistic effect, and a new treatment thought is provided for overcoming tumor drug resistance.
Owner:BEIJING INST OF TECH

Topical composition comprised of cod liver oil for treating wounds and skin disorders

Disclosed is a topical anhydrous, homogenous pharmaceutical composition for treating skin disorder and wounds comprising cod liver oil, hempseed oil, monolaurin, medium chain triglycerides (“MCT”), free fatty acids, sea salt, and vegetable oil selected from the group consisting of red palm concentrate, coconut oil, and red palm oil and combination thereof and optionally fish collagen, ascorbyl palmitate, thickening agent, such as beeswax, red palm concentrate and cetyl ester.
Owner:OMEZA HOLDINGS INC

Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereof

Provided herein are compounds having the structure of Formula Ia, wherein the compounds comprise a therapeutic agent having the configuration of [diacid]-[linker]-[an amylin analog], in which the amylin analog has the amino acid sequence of SEQ ID NO: 20, with a proviso that the amino acid sequence comprises one or more of the following amino acid substitutions: N14E, V17R, Y37P, F15E, L16E, V17E, or any combination thereof, and the compounds have an anion: cation molar ratio of from about 1:1 to about 1:3, and methods of using thereof for the treatment of metabolic diseases or disorders, including type 1 diabetes, type 2 diabetes, obesity, overweight, and nonalcoholic steatohepatitis, and for reducing weight in a subject in need thereof.
Owner:I2O THERAPEUTICS INC